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Objectives: To evaluate the cost-effectiveness of modern anti-Parkinson 
drugs in monotherapy early stages of Parkinson’s disease (PD) in the Russian 
Federation. MethOds: For analysis of market data regarding PD treatment prod-
ucts we used IMS Health Russia database (2014). The target population was newly 
diagnosed PD patients over 60 years in the early clinical stages according to Hoehn 
and Yahr functional scale (HY I-III stage). The time horizon for this analysis was 
taken for 1-year period. Comparison drugs: piribedil CR, pramipexole ER, ropin-
irole ER and rasagiline. Effectiveness of anti-Parkinson drugs was evaluated as 
the percentage of patients who responded to treatment. In the analysis we took 
into account the costs associated with adverse drugs reactions (ADR). Discounting 
outcomes and costs was not conducted because the time horizon of the analysis 
did not exceed 1 year. Bivariate sensitivity analysis (SA) was performed. Results: 
The cost of the 1st year therapy of compared drugs was: 28,822, 20,810, 57,449 
and 54,332 rubles for piribedil CR, pramipexole ER, ropinirole ER and rasagiline 
respectively. Total therapy cost was estimated based on 1st year therapy cost and 
ADR costs. Total costs for comparator drugs constituted 28,930, 21,009, 57,576 and 
54,381 rubles for piribedil CR, pramipexole ER, ropinirole ER and rasagiline respec-
tively. The effectiveness of comparator drugs was 42.0%, 66.7%, 64.0%, and 64.0% 
for piribedil CR, pramipexole ER, ropinirole ER and rasagiline respectively. During 
the analysis we obtained results indicating that pramipexole ER has the lowest 
CER – 31,499 rub. cOnclusiOns: Pramipexole ER has the lowest CER (31,499 rub. 
per year for one patient responded to anti-Parkinson therapy). SA confirmed these 
results. Pramipexole ER was the dominant strategy for PD treatment, demonstrat-
ing higher effectiveness at lower costs.
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Objectives: Multiple sclerosis (MS) is a neurodegenerative and demyelinating 
disease of the central nervous system leading to impaired nerve impulse conduc-
tion with concomitant symptoms such as weakness in limbs, muscle stiffness or 
spasms, paralysis, problems with vision, fatigue and cognitive changes. Current 
disease modifying therapies indicated for first-line treatment of relapsing-remit-
ting MS (RRMS) in Sweden are injection therapies including beta interferons and 
glatiramer acetate, and the two recently approved oral treatments delayed-relase 
dimethyl fumarate (DMF; also known as gastro-resistant DMF) and teriflunomide. 
The objective of the present study was to evaluate the cost-effectiveness of DMF 
(versus the least costly first-line alternative interferon beta-1b MethOds: The 
analyses were performed in a Markov model with health states describing the 
management and consequences of RRMS in terms of relapses and progression 
through a series of disability states, based upon the Kurtzke Expanded Disability 
Status Scale (EDSS). The societal and the payer perspectives for a time horizon 
of 30 years were applied for the base-case analyses. Results: The results from 
the societal as well as the payer perspective showed that DMF was dominant as 
compared to interferon beta for the treatment of RRMS in Sweden, offering cost-
savings and QALY gain of 0.476. One-way sensitivity analyses (±25% of base-case) 
showed that DMF remained dominant in all variations tested with the exception of 
the treatment effect on disability progression rate. Probabilistic sensitivity analy-
ses from the societal perspective showed that DMF was dominant in 61% of the 
simulations. cOnclusiOns: In the present analyses DMF dominated interferon 
beta-1b from the societal as well as payer perspective, but showed sensitivity to 
variations in the variable treatment effect on disease progression. This study was 
sponsored by Biogen.
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Objectives: Botulinum neurotoxin type A is effective in managing cervical dystonia 
(CD), a disorder causing painful and involuntary contraction of neck and shoulder 
muscles and abnormal posture in middle-aged adults. However, the cost-effective-
ness of abobotulinumtoxinA for the treatment of CD in the United Kingdom (UK) 
has not been evaluated. MethOds: A Markov model was developed from the UK 
payer perspective to evaluate the cost-effectiveness of abobotulinumtoxinA com-
pared to best supportive care (BSC) with a lifetime horizon and health states for 
response, non-response, secondary non-response and BSC in CD patients (mean 
age: 53 years; 37% male population). The clinical improvement in Toronto Western 
Spasmodic Torticollis Rating Scale (TWSTRS) was mapped to utility using the 
data from the randomized Phase III trial of abobotulinumtoxinA (NCT00288509). 
Healthcare resource costs and other model inputs were obtained from British 
National Formulary, Personal Social Services Research Unit, published literature or 
clinical experts. Costs and outcomes were discounted at 3.5% per annum. Results: 
The incremental lifetime quality adjusted life years (QALY) gained in the abobotu-
linumtoxinA arm compared to BSC was 0.25 per patient, whereas the incremental 
cost was £6,234, corresponding to an incremental cost-effectiveness ratio of £24,936 
per QALY. One-way sensitivity analyses showed that the results are sensitive to 
the proportion of responders to abobotulinumtoxinA at first injection, duration 
of the reinjection interval, the number of cycles of reinjection allowed amongst 
primary non-responders and any difference in TWSTRS value at baseline that may 
exist between patients in BSC and abobotulinumtoxinA arm. Probabilistic sensi-
tivity analysis showed abobotulinumtoxinA to be cost-effective 41% of times in 
5000 Monte Carlo simulations, at a threshold of £20,000 per QALY. cOnclusiOns: 
Using abobotulinumtoxinA in adult patients with CD was not only found to be cost-
effective at an acceptable willingness-to-pay threshold in the UK but also provides 
additional quality of life gains.
The literature review retrieved 5,676 studies of which 19 fulfilled the eligibility cri-
teria. Sixteen articles compared different pharmaceutical therapies and 3 studies 
compared non-pharmacological treatments to pharmaceutical therapies. Eleven 
studies included economic evaluations on refractory epilepsy, 4 on Lennox-Gastaut 
Syndrome and 5 on different epileptic seizure types. Eight were cost-effectiveness 
analyses, 10 were cost-utility analyses and one presented both. Ten studies com-
pared newer adjunctive antiepileptic drugs (AEDs) to standard therapy alone. Among 
the various adjunctive AEDs, lacosamide and oxcarbazepine were the most cost-
effective AEDs compared to standard therapy alone, with ICERs varying from domi-
nant to (2015US)$47,383/QALY. One study also presented 5 ICERs on newer AEDs used 
as monotherapy compared to standard therapy and 4 were dominated or subject to 
extended dominance. Seven studies compared different adjunctive AEDs to each 
other. Rufinamide was the most studied AED (n= 3) and ICERs presented ranged 
from (2015US)$263,407/QALY to $391,129/QALY when compared to lamotrigine in 
Lennox-Gastaut syndrome. Among the studies comparing non-pharmacological 
treatments to standard therapy, the ICERs ranged from (2015US)$4,098/QALY to 
$117,505/QALY. cOnclusiOns: Results suggest that lacosamide and oxcarbazepine 
are cost-effective adjunctive AEDs compared to standard therapy alone. However, 
newer AEDs used as monotherapy seem not cost-effective whereas alternative 
non-pharmacological interventions could be cost-effective compared to standard 
therapy. This review provides an overview of the cost-effectiveness of treatments in 
epilepsy and could serve in the realization of future economic evaluations.
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Objectives: New therapies for Relapsing-Remitting Multiple Sclerosis have 
recently emerged, adding to the complexity of decision-making. The objective of this 
abstract was to assess cost-effectiveness of dimethyl fumarate (DMF), teriflunomide, 
alemtuzumab, natalizumab and fingolimod versus their phase III comparators in 
Spain. MethOds: Annual costs per relapse avoided with each therapy versus their 
trial comparators were estimated. When subgroup analyses from clinical trials were 
available, they were used it to differentiate efficiency in different patient subgroups 
or to approximate populations to treatment indication. Efficacy inputs were pre-
viously published as Annualized Relapse Rates (ARR) from trials or trial subgroup 
analyses. Economic inputs included drug and relapse costs; drug annual costs were 
calculated according to Spanish list prices, and an average relapse cost of 1.641,67€ 
was applied according to a recent publication. Results: Cost per relapse avoided was 
63.177€ and 83.458€ for DMF vs placebo in naïve and pre-treated patients, respectively. 
Teriflunomide resulted in 74.630€ to 79.117€ per relapse avoided when compared to 
placebo, and had higher ARR and lower costs than subcutaneous interferon-beta-1a, 
resulting in an incremental cost of 35.520€ per relapse avoided for interferon vs teri-
flunomide. Alemtuzumab had a cost per relapse avoided of 58.951€ vs subcutaneous 
interferon-beta-1a in previously treated patients. Result for natalizumab was 37.154€ 
vs placebo, while the incremental cost per event avoided with fingolimod in previously 
treated patients was 30.493€ vs intramuscular interferon-beta-1a. cOnclusiOns: 
Analysis of incremental costs per relapse avoided ranged from 30.493€ for fingolimod 
vs intramuscular interferon-beta-1a to 83.458€ for DMF vs placebo, both in pre-treated 
patients. Drug comparator and patient populations aimed to be determinant factors 
to explain relative efficiencies.
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Objectives: Cataplexy is a frequently observed symptom of narcolepsy which is 
treated mainly with antidepressants. However, as their success rate is very low, 
the unmet need is considerable. Sodium Oxybate is a novel treatment and the 
first product developed to treat cataplexy in patients with narcolepsy. Given the 
low prevalence and high unmet need, inclusion of sodium oxybate in the posi-
tive list of the Social Security Institution of Turkey is very important. This study 
aims at providing evidence about the cost effectiveness of sodium oxybate in 
Turkey. MethOds: As narcolepsy is a rare disease and sodium oxybate is the first 
product to treat the disease, there isn’t a global economic model to be adapted 
to the Turkish setting. That is why a simple decision model was developed to 
estimate the cost effectiveness. The results of the clinical trials of the product 
revealed that the annual number of cataplexy attacks prevented with placebo was 
671, whereas the figure was 1,845 with sodium oxybate. As the Turkish guidelines 
for cost effectiveness analysis doesn’t allow using QALY data, only the number 
of prevented cataplexy attacks were used as an outcome measure. For the cost 
section, only the annual cost of sodium oxybate was used to calculate the incre-
mental cost effectiveness ratio. The study was undertaken from the payer’s per-
spective. Results: The cost per cataplexy attack prevented was found as 17.12 
TL. As the incremental cataplexy attacks prevented was 1,174 annually, the total 
cost per prevented cataplexy attacks was estimated as 20.098 TL. Although Turkey 
doesn’t have an explicit threshold to be used in cost effectiveness decisions, this 
figure is acceptable given the fact that narcolepsy is a rare disease and there is 
a huge unmet need. cOnclusiOns: Inclusion of sodium oxybate to the Turkish 
positive list of drugs is a cost effective option.
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to disability progression rate. cOnclusiOns: The incremental cost effectiveness 
ratio of 17.433 € is considerably below the threshold usually accepted for financing 
medicines in Portugal (around 30.000 € /QALY). Dimethyl Fumarate should be seen 
as a cost-effective therapy for the Portuguese setting.
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Objectives: Peginterferon beta-1a is indicated for the treatment of adult relaps-
ing remitting multiple sclerosis (RRMS) patients. The efficacy and safety of sub-
cutaneous (SC) peginterferon beta-1a (PEGIFN beta-1a) was demonstrated in the 
randomised double blind Phase 3 placebo-controlled ADVANCE trial. We assessed 
the cost-effectiveness of PEGIFN beta-1a compared with other injectable first-line 
RRMS treatments in Italy. MethOds: The analysis was developed through a Markov 
model with lifetime simulation in the perspective of the Italian National Healthcare 
Service (NHS). Outcomes measurements included life years (LYs), quality adjusted 
life years (QALYs), lifetime costs, and incremental cost-effectiveness ratio (ICER). 
The natural progression of disease used in the model was based on previously 
published literature and modelling exercises. Treatment efficacy (reduction of 
disability progression and reduction of relapse rate) was derived from published 
mixed treatment comparison. Unit costs were based on Italian 2015 prices and 
tariffs, and the published literature. A 3.5% discount rate was applied to costs and 
benefits. One-way and probabilistic sensitivity analyses were developed and cost-
effectiveness acceptability curves generated. Results: PEGIFN beta-1a provided 
numerically longer patient survival (19.94 vs. 19.68-19.81 discounted LYs, respec-
tively), and QALY (9.07 vs 8.06 - 8.55 discounted QALY, respectively). The ICER for 
SC PEGIFN beta-1a vs. IM interferon beta-1a 30mcg; SC interferon beta-1a 22mcg; 
SC interferon beta-1b 250mcg; or glatiramer acetate 20mcg was € 11,018; € 12,504; 
€ 10,477; € 16,599; € 21,536 per QALY respectively. Peginterferon beta-1a dominated 
interferon beta-1a 44mcg. The outcomes of the sensitivity analyses confirmed the 
robustness of these results. cOnclusiOns: PEGIFN beta-1a was dominant vs SC 
interferon beta-1a 44mcg and cost-effective when compared with other approved 
first-line injectable treatments for RRMS in Italy. The ICERs fall well below the com-
monly accepted thresholds of € 30,000 - € 50,000 per QALY gained demonstrating that 
PEGIFN beta-1a is a cost effective treatment.
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Objectives: To examine the economic burden and health care utilization for 
patients diagnosed with Parkinson’s disease using linked data from Medicare and 
the Long Term Care (LTC) Minimum Data Set (MDS). MethOds: Patients were 
included in the study if they had at least one diagnosis claim for Parkinson’s disease 
(International Classification of Diseases, 9thRevision, Clinical Modification code 332.
xx) during the identification period (01JUL2008-31DEC2010). The first Parkinson’s dis-
ease diagnosis claim date was designated as the index date. Patients were required 
to be age ≥ 65 and have continuous health plan enrollment with medical benefits 
for 6 months pre- and post-index date. Residents in a LTC facility were defined as 
study patients using two quarterly assessments recorded in the MDS during the 
6-month baseline period. Demographic and clinical characteristics and follow-up 
health care costs and utilizations were described. Results: After 1:1 matching, 
1,620 patients were included in each group (disease and control patients), and the 
baseline characteristics were well-balanced. Patients with Parkinson’s disease 
were more likely to have inpatient stays (14.26% vs. 9.51%, p< 0.0001), outpatient 
visits (47.72% vs. 41.11%, p= 0.0002), skilled nursing facility (SNF) visits (20.37% vs. 
4.51%, p< 0.0001), hospice visits (8.64% vs. 1.36%, p< 0.0001), and part D pharmacy 
visit (62.65% vs. 53.33%, p< 0.0001). Compared to control patients, higher all-cause 
health care costs were also observed for Parkinson’s disease patients, including 
inpatient costs ($2,451 vs. $1,301, p< 0.0001), SNF costs ($2,503 vs. $778, p< 0.0001), 
hospice costs ($1,164 vs. $245, p< 0.0001), total outpatient costs ($4,477 vs. $1,304, 
p< 0.0001), pharmacy costs ($695 vs. $1,399, p< 0.0001) and total costs ($9,775 vs. 
$5,314, p< 0.0001). cOnclusiOns: During a period of 12 months, patients diag-
nosed with Parkinson’s disease had higher health care utilization and costs than 
matched control patients.
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Objectives: To evaluate the cost-utility of modern anti-Parkinson drugs in mono-
therapy early stages of Parkinson’s disease (PD) in the Russian Federation. MethOds: 
For analysis of market data regarding PD treatment products we used IMS 
Health Russia database (2014). The target population was newly diagnosed 
PD patients over 60 years in the early clinical stages according to Hoehn and Yahr 
functional scale (HY I-III stage). Comparison drugs: pramipexole ER, piribedil CR, 
ropinirole ER and rasagiline. Utility effect of anti-Parkinson drugs was evaluated 
by quantitative scale UPDRS – Unified Parkinson’s Disease Rating Scale, part II 
(daily activities) and III (the severity of motor disorders). In the analysis we took 
into account the costs associated with adverse drugs reactions (ADR). Discounting 
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Objectives: Relapsing-remitting multiple sclerosis (RRMS) is characterized by 
periods of relapse and remission, leading to progressive accumulation of disability. 
Disease-modifying treatments (DMTs) are used in treatment of MS to reduce the 
frequency of relapses and disease progression. The study objective was to compare 
the cost effectiveness of dimethyl fumarate with teriflunomide for treatment of 
RRMS in a Danish setting from a healthcare and societal perspective. MethOds: In 
a cohort based Markov model patients progress through a series of disability states 
based on the Expanded Disability Status Scale (EDSS). At any time, patients have 
fixed probabilities of progression and relapse dependent on RRMS or secondary 
progressive MS (SPMS) status and the EDSS score. Mixed treatment comparisons 
determined the clinical efficacy of the treatment options that in the model act to 
delay the progression of the disease and reduce the relapse frequency in patients 
with RRMS. The model uses one-year cycles, and the base case time frame of the 
analysis was 30 years. Healthcare and societal costs (including productivity losses) 
and QALYs for each patient are directly linked to the time the patient spends in each 
EDSS state. Results: In the base case, treatment with dimethyl fumarate compared 
with teriflunomide is associated with a QALY-gain of 0.21 QALYs, at lower healthcare 
(DKK -87,547) and societal costs (DKK -132,524), implying that dimethyl fumarate is 
a dominant strategy. Probabilistic sensitivity analyses were performed, showing that 
dimethyl fumarate dominates from a healthcare and societal perspective in 67.6% and 
72.9% of 5,000 simulations, respectively. One-way sensitivity analyses showed that 
dimethyl fumarate is costsaving from a healthcare and societal perspective at a yearly 
drug-cost difference up to DKK 46,000 and DKK 58,000, respectively. cOnclusiOns: 
The analysis demonstrates that dimethyl fumarate is a cost-effective and cost saving 
treatment alternative from a Danish healthcare and societal perspective.
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Objectives: To assess the cost-effectiveness of fingolimod as a second-line therapy 
for patients with highly active relapsing-remitting multiple sclerosis using a Markov 
model applied to Greece. MethOds: The analysis was undertaken from the perspec-
tive of the Greek NHS and the model was populated with data drawn from the litera-
ture and national published sources. Two cohorts of patients, one for the intervention 
and one for the comparator treatment sequence, are simulated in the model over a 50 
year time horizon. Each patient in a given cohort is treated with four lines of treatment 
or removed from treatment due to death. The analysis is based on the subgroup of 
highly active relapsing-remitting MS patients despite treatment with a previous DMT 
as this represents fingolimod’s main target population. The discount rate was 3.5% 
per year. Extensive sensitivity analysis was also undertaken. Results: This analysis 
has shown that the use of fingolimod as second-line treatment compared to DMF in 
these patients results in an incremental cost-effectiveness ratio of € 32,939 per QALY 
gained over a patient’s lifetime for Interferon-beta1-aSC – Fingolimod – BSC – BSC 
compared to Interferon-beta1-aSC – DMF – BSC – BSC, in € 33,783 for Interferon-beta1-
aIM – Fingolimod – BSC - BSC compared to Interferon-beta1-aIM – DMF – BSC - BSC and 
in € 32,998 for Glatiramer acetate – Fingolimod – BSC – BSC compared to Glatiramer 
acetate – DMF – BSC – BSC. The above estimates did not vary substantially across a 
range of assumptions investigated within the sensitivity analyses. cOnclusiOns: 
The use of fingolimod as second-line treatment compared to DMF in patients with 
highly active relapsing-remitting MS in a Greek health care setting results in long-
term clinical benefit and it is associated with a modest incremental cost-effectiveness 
ratio that most decision makers would consider acceptable especially for such a 
disabling disease.
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Objectives: This study aims to assess the cost-utility of delayed-release dime-
thyl fumarate (DMF; also known as gastro-resistant DMF), a new disease modify-
ing therapy (DMTs), in treatment of patients with Relapsing-Remitting MS (RRMS) 
in Portugal. MethOds: A 1-year cycle Markov model based on the ScHARR MS 
Model was used to simulate disease progression, measured by Kurtzke Expanded 
Disability Status Scale (EDSS), relapses, and conversion to secondary-progressive MS 
(SPMS). It was assumed that patients could discontinue first line treatment (DMF or 
glatiramer acetate) and switch to a second line, but would stop any treatment after 
conversion to SPMS or progression to EDSS7. Clinical inputs for active treatments 
(disability progression, relapse rate and discontinuation of ITT population) were 
estimated on a mixed treatment comparison while natural history was based on 
DMF clinical trials and London Ontario database. Utility weights for patients and 
caregivers were derived from DMF clinical trials and the UK-MS Survey. Resource 
consumption by EDSS and due to relapses was based on published literature 
relevant to the Portuguese setting. Unit costs were obtained from official sources. 
The analysis was conducted from the societal perspective, assuming a time horizon 
of 50 years and a discount rate of 5%, for both costs and benefits. Results: When 
compared to glatiramer acetate, DMF was associated with delay in progression and 
reduction in annualized relapse rate, resulting in a gain of 0.39 quality adjusted life 
years (QALYs), but implying a cost increase of 8.971 € . The incremental cost per 
QALY is thus 17.433 € . Sensitivity analysis shows that results are more sensitive 
